Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Study Summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

Conditions

Hypertriglyceridemia

Interventions / Drugs

Plozasiran Injection Placebo

View on ClinicalTrials.gov ↗

Sponsor

ARWR

Arrowhead Pharmaceuticals

RNAi Therapeutics

D36/100

Study Details

Enrollment1456 participants

Primary Completion—

Lead SponsorArrowhead Pharmaceuticals

Data Retrieved2026-04-11 02:54:36.141173+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.